IRRITABLE BOWEL SYNDROME Arnold Wald, M.D., AGA-F University of Wisconsin School of Medicine & Public Health, Madison, WI.

Slides:



Advertisements
Similar presentations
Diagnostic Work-up. There is no specific laboratory or imaging test to diagnose irritable bowel syndrome. Currently the diagnosis of IBS relies on meeting.
Advertisements

Irritable bowel syndrome in adults
Case Studies in Luminal Gastroenterology Adam Harris Consultant Gastroenterologist The Spire Tunbridge Wells Hospital.
Diarrhea By: Rahul Malhotra. What is Diarrhea? Diarrhea is loose, watery stools. Having diarrhea means passing loose stools three or more times a day.
Giardia Lamblia. Giardia Giardia lamblia is a flagellated protozoan that infects the duodenum and small intestine. range from asymptomatic colonization.
IBS or IBD: a N.I.C.E. Way to Tell
Ulcerative Colitis.
SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN Prof. Dr: Mona Abu Zekry -Professor of Pediatrics Head.
Overview of Irritable Bowel Syndrome
FODMAPS: a review of the current literature and more… Michael Bizeau, PhD Metropolitan State University of Denver.
Lower Gastrointestinal Tract KNH 411. © 2007 Thomson - Wadsworth.
IRRITABLE BOWEL SYNDROME (IBS)
IBS Irritable Bowel syndrome Prince Sattam Bin AbdulAziz University College Of Pharmacy Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department.
Irritable Bowel Syndrome Sam Thomson 3 rd November 2010.
Lower Gastrointestinal Tract KNH 411. © 2007 Thomson - Wadsworth.
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review Journal club presentation
Management of irritable bowel syndrome (IBS) WORKSHOP Dimitris Karanasios.
Ian Arnott Consultant Gastroenterologist Western General Hospital Edinburgh The Use of Faecal Calprotectin in Primary Care.
Lower Gastrointestinal Tract KNH 411. © 2007 Thomson - Wadsworth.
IBS In The Elderly Monica J. Cox ARNP-BC, MSN, MPH Geriatric Nurse Practitioner G.I. Nurse Practitioner Borland-Groover Clinic Jacksonville, Florida.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
Managing IBS patients Dr Sameer Zar MBBS FRCP PhD Consultant Gastroenterologist Epsom & St Helier NHS Trust.
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
Copyright HD Scientific All Rights Reserved 1 When Is Intestinal Gas Dangerous? Dangerous?
Irritable Bowel Syndrome 1481 Nadeem Khan March 2, 2015.
Focus on Irritable Bowel Syndrome (IBS)
COMMON OPD PATIENT. 29 y.o. lady 18 month history loose stool  2-3 per day  Begins just soft, then looser –”explosive”  Night ok  No blood, occasional.
Dyspepsia MAHSA KHODADOOSTAN-- GASTROENTROLOGIST.
IRRITABLE BOWEL SYNDROME
Should we Screen for Celiac Disease in IBS? Brennan Spiegel, MD, MSHS.
Irritable Bowel Syndrome By: Rocco Paolino. Definition A combination of intermittent abdominal pain, constipation and/or diarrhea.
1 Ellora Islam Jodie Ly Tony Davi Sonaiya Kelley.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
NYU Medical Grand Rounds Clinical Vignette Andy Levy, MD PGY-2 March 26, 2013 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Jackie Skradski Pharm.D. Candidate 2016 Ferris State University College of Pharmacy February 25, 2015.
Management of Irritable Bowel Syndrome (IBS) in Family Medicine Meera Kaur, PhD, RD, CDE Assistant Professor, Family Medicine University of Manitoba, Canada.
Habit disorders Dr. Ibrahim Khasraw Lecturer in Pediatrics School of Medicine Sulaimani University of.
Conclusions Sidney Cohen, MD Chairman, Department of Medicine Temple University School of Medicine Philadelphia, Pennsylvania Sidney Cohen, MD Chairman,
Are patients with chronic diseases a new challenge to general practice? Patients with irritable bowel syndrome in general practice Patients with irritable.
FLATUS FRIEND OR FOE EVERYTHING YOU WANTED TO KNOW BUT WERE AFRAID TO ASK MARSHA JOHNSON SCHULTE DNP, ANP-BC.
Giardiasis Giardia Enteritis Lambliasis Beaver Fever.
Anatomy and Physiology & Pathophysiology
Changes in bowel movement-IBS Mohammed Alwahibi Khalid Alsadhan Walid Alkhamis.
Change in Bowel Movement Mohammed Abaalkhail Muath Alsoliman Badr Almosned.
Dr. Zahoor 1. A 42 year old Saudi male was presented to us with two years of history of excessive hair fall and flatulence with recent worsening of his.
IRRITABLE BOWEL SYNDROME Barbara L. Slee, M.D.. IBS Epidemiology and pathophysiology Symptoms and signs of Dx Appropriate Work-up Treatment.
Lower Gastrointestinal Tract KNH 411. © 2007 Thomson - Wadsworth.
Shad Johnson MPAS, PA-C Southeast Idaho Gastroenterology.
The Use of Faecal Calprotectin in Primary Care
Irritable Bowel Syndrome
Changes in bowel movements (IBS)
Focus on Irritable Bowel Syndrome (IBS)
Antidepressant-Induced Sexual Dysfunction
Diagnosis and Treatment of IBS
Presenting with IBS symptoms, baseline assessment.
IRRITABLE BOWEL SYNDROME
The Effects of a Low-FODMAP Diet on Treatment of Irritable Bowel Syndrome in Patients Melanie Palmer.
Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation  Satish S.C. Rao, Eamonn M.M. Quigley,
Appendix Appendix : is a small, finger-shaped that projects from colon on the lower right side of abdomen. Appendicitis: is inflammation of the appendix.
iPad Instructions iPad Instructions Polling Question.
Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation  Satish S.C. Rao, Eamonn M.M. Quigley,
IRRITABLE BOWEL SYNDROME
Charles D. Gerson, Mary-Joan Gerson 
Rome IV: What Has Changed? Rome IV IBS Subtypes.
Volume 151, Issue 6, Pages (December 2016)
The Use of Faecal Calprotectin in Primary Care
Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis  Elizabeth J. Videlock, Vivian.
FIGURE 1 PRISMA flow diagram of studies in systematic review
Volume 139, Issue 6, Pages e2 (December 2010)
Presentation transcript:

IRRITABLE BOWEL SYNDROME Arnold Wald, M.D., AGA-F University of Wisconsin School of Medicine & Public Health, Madison, WI

1. A 35 y.o. teacher develops a diarrheal illness while on a trip to Mexico. Ciprofloxacin and loperamide are taken for 3 days but postprandial crampy abdominal pain, intermittent loose stools and bloating persist for 2 months. There is no weight loss, blood in the stools, arthritis, rash or fever but the patient complains of fatigue. Physical examination is normal, stool is hemoccult negative and CBC and stool studies are normal. Which of the following statements about this condition is correct? a)It is more likely to occur if the teacher is female and anxious b)It is more likely to occur if the initial cause of the diarrhea was ST-producing E. coli 0157:H7 c)It is less likely to occur if the patient received antibiotics for the initial diarrheal illness d)The diagnosis is best made with colonoscopy and biopsy of a normal appearing mucosa

POST-INFECTIOUS IBS 20% of IBS pts describe acute infectious prodrome Occurs in 5-25% after bacterial enteritis Diarrhea predominant No difference among pathogens (bacterial and viral) Greater likelihood in females, long duration of diarrhea, and with use of antibiotics Occurs in subjects with anxiety, depression

2. A 33 year old woman presents with a 3 year history of intermittent abdominal cramps, excessive bloating, intermittent diarrhea and no weight loss. Her physical examination is normal as is a CBC and C-reactive protein. Which of the following is correct? a) She has an increased risk of celiac disease and should be tested with serology. b) She has a 20% chance of having small intestinal bacterial overgrowth and should be tested with breath analysis. c)She is likely to have no increase in either small intestine or colonic gas volume. d)She is likely to have increased colonic methane gas production.

DIAGNOSTIC APPROACH TO PATIENT WITH IBS SYMPTOMS (NO “ALARM SIGNS”) CBC Hemoccult Routine colon cancer screening at ages > 50 yrs. (ACG Functional GI Disorders Task Force, 2002)

Prevalence of Abnormal Serum Tests for Celiac Disease IBS (n=492)Healthy Control (n=458) AGA IgA 1.6% 1.8% EMA 0.6% 0.4% tTG IgA 1.2% 0.4% DQ2 33% 39% DQ8 16% 18% Cash BD, et al. Gastroenterol 2011, 141:

PROMETHEUS ® IBS Diagnostic-NOT READY FOR CLINICAL USE!! Performance of Validation Cohort at 50% Disease Prevalence (n=516) Sensitivity50% Specificity88% Positive predictive value (PPV)81% Negative predictive value (NPV)64% Accuracy70% The selected validation cohort included 50% from patients with IBS, 36% from patients with non-IBS disorders (IBD, celiac disease, or functional GI disorders), and 14% healthy controls

Small Intestinal Bacterial Overgrowth and IBS Hypothesis is based upon poor methodology and erroneous conclusions. Original studies not reproduced by others using either similar and/or better methods. (Walters, Posserud) Use of antibiotics to suppress colon bacteria effective in some patients with IBS.

3.Which of the following treatments for IBS exhibits the greatest benefit over placebo in randomized controlled trials? a)Lubiprostone b)Rifaximin c)A good physician-patient relationship d)Hypnosis

6 0 Global Improvement 70 0 Adequate Relief Percentage 12 0 Quality of Life Mean Change Waiting List (n=87) Limited (n=88) Augmented (n=87) Adapted from Kaptchuk, et al BMJ 2008 Patient-practitioner relationship is the most important component of the placebo effect in IBS

Lubiprostone for IBS-C: Overall response rate at week 12 7/2/201512TKGR-IBSC Adapted from Drossman et al, APT 2009; 29: 329 ***p=0.001 vs placebo Placebo (n=387) Lubiprostone 8 µg bid (n=780) *** *** 0 25% Pooled data from 2 Phase III studies

Rifaximin: Global Improvement Measure Outcomes Response rates (%)WeightTherapeutic Gain NNT RifaximinPlacebo Sharara %18%5.6 Pimentel %23.5%4.3 Lembo %8.1%12.3 Target %9.6%10.4 Target %8.4%11.9 Overall %9.1%11.0

Gut-directed hypnotherapy effective in improving IBS symptoms 6 RCTs; patients refractory to standard management –reduces anxiety and improves symptom control in majority of patients with refractory IBS Cochrane review of 4 randomized clinical studies (n=147) –hypnotherapy improved abdominal pain and overall IBS symptoms –results should be interpreted with caution due to poor methodological quality and small sample sizes Hypnotherapy Hypnotherapy 7/2/201514TKGR-IBSC Cochrane Database of Systematic Reviews 2007

4. A 44 y.o. woman with diarrhea predominant IBS is started on nortriptyline 10 mg daily but she complains of fatigue, disorientation and palpitations which persist after 10 days. Her IBS symptoms are unchanged. The most appropriate course of action is: a)Continue the drug for another 2 weeks as she will gradually adapt to side effects b) Discontinue the drug; start linaclotide 145 mcg daily c) Discontinue the drug; refer her for cognitive behavioral therapy d) Discontinue the drug; prescribe desipramine 10 mg daily

Psychotropic agents in IBS Antidepressants in small doses improve functional pain independently of psychotropic properties Known side effects can be useful in IBS SSRIs better than placebo for global improvement TCAs better than placebo for abdominal pain and symptom scores

Desipramine improves IBS symptoms 17 Modified from Drossman et al, Gastroenterology 2003; 125: 19–31 n=431 ** **p=0.006 vs placebo Composite symptom scale improvement % 60% 49% 73% Placebo Desipramine Intention-to-treat analysis Per-protocol analysis

Linaclotide for IBS-C Linaclotide for IBS-C 7/2/2015 Rao, et al. Am J Gastro 2012 NNT = 7.9 *p < Placebo (n=335) Linaclotide 290 µg (n=312) *** 21% 33.6%* 0% 60% FDA endpoint 30% Percent response FDA endpoint: > 30% reduction in abdominal pain AND increase > 1 CSBM for > 6 of 12 weeks

5.A 30 y.o. normal weight woman presents because of intermittent diarrhea, bloating, flatulence and abdominal discomfort of many years duration. Her physical examination is normal, as is a CBC and sedimentation rate. She has tried simethicone, Gas X and Beano ® with no improvement. She does not smoke, consume milk products or drink carbonated beverages. Which of the following would be the most cost effective approach? a)Rifaxamin b) FODMAP restricted diet c)Citalopram d)Mediterranean diet

FODMAPs (Fermentable oligo-, di- and monosaccharides and polyols) Fructans (onions, wheat, artichokes) Galactans (legumes, cabbage, Brussel sprouts) Lactose Sorbitol Xylitol Mannitol Sucralose (Splenda)

% improved Bloating P<0.002 Abd Pain P<0.02 Flatulence P<0.001 Composite Score P<0.001 Std (n=35) FODMAP (n=39) Low FODMAP Diet is more effective than standard diet in IBS Staudacher HM, et al., J Hum Nutr Diet 2011 Oct; 24 (5):

Low FODMAP Diet Reduces Symptoms of IBS From Halmos et al, Gastro 2014

Rifaximin: Bloating AuthorWeightOR95% CI P value Pimentel2.5% , Lembo26% , Target 133.9% , Target 237.5% , Overall100% ,1.89<0.001 Favors Placebo Favors Rifaximin

TREATMENT OF BLOATING AND IBS: Diet or Antibiotic? * January 2014 RifaximinFODMAP Diet Mechanism of action Decreases colonic bacteria by killing bugs Decreases colonic bacteria by reducing dietary CHO Cost $910/42 tablets*Cost of Food Additional benefit Does not promote weight loss Might promote weight loss

References 1.ACG IBS Task Force, An evidence-based position statement on the management of IBS. Am J Gastroenterol 2009;104:S Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid(online) 2012 Jan 6 pii0410